Abstract:Introduction: CD19 CAR T cells induce complete remissions in ≥40%of heavily pretreated patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). However, a significant proportion of patients progress early after therapy. Thus, to prospectively identify patients most suitable for currently available commercial CAR T-cell products, we assessed the predictive value of clinical and laboratory parameters for PFS in r/r DLBCL patients treated with Axicabtagene Ciloleucel or Tisagenlecleucel at o… Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.